Background: In 2020, melanoma exhibited the 5th highest incidence rate of all cancers in the US. While metastatic melanoma constitutes only 4% of new melanoma cases, the 5-year survival rate of metastatic melanoma is 27% [1]. Immune Checkpoint Inhibitors (ICIs) were the first drugs to significantly improve the 5-year survival of late-stage melanoma patients; these [...]

Case Presentation: We report the case of a 45-year-old female with stage IA triple-negative breast cancer treated with neoadjuvant chemotherapy and pembrolizumab who developed secondary adrenal insufficiency due to adrenocorticotropic hormone (ACTH) deficiency six months after stopping the immune checkpoint inhibitor. She presented with persistent nausea, vomiting, weight loss, and altered mental status. Laboratory results [...]